Open access
Jul 2026
Tumor-derived annexin A1 drives lenvatinib resistance by regulating SOX2/STAT3/S100A6 feedback loop and M2 macrophage polarization in hepatocellular carcinoma
Lenvatinib has been approved by the FDA as a front-line treatment for advanced hepatocellular carcinoma (HCC), but its survival benefits are limited by acquired drug resistance. In this study, we investigate the mechanisms underlying lenvatinib resistance in HCC by establishing lenvatinib-resistant (LenR) patient-d...
Catherine Yu Jia Gu, C. Leung, R. Leung et al.
· Cell Death & Disease · 0 citations